肝硬化并发自发性细菌性腹膜炎诊治现状

doi:10.3969/j.issn.1672-5069.2022.05.003

Abstract

Luo Nan, Li Rongkuan. Spontaneous bacterial peritonitis in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2022, 25(5): 616-619.

[1]Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol, 2012,56( Suppl 1):S1-12.
[2]Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology, 2010,139(4):1246-1256,e1-5.
[3]European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018,69(2):406-60.
[4]Shizuma T. Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review. World J Hepatol, 2018,10(2):254-266.
[5]Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology,2002,35(1):140-148.
[6]Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011,54(2):562-572.
[7]Pardo A, Bartoli R, Lorenzo-Zuniga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology, 2000,31(4):858-863.
[8]Slocum MM, Sittig KM, Specian RD, et al. Absence of intestinal bile promotes bacterial translocation. Am Surg, 1992,58(5):305-310.
[9]Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol, 2014,60(1):197-209.
[10] Piano S, Brocca A, Mareso S, et al. Infections complicating cirrhosis. Liver Int, 2018,38 (Suppl 1):126-133.
[11] Piotrowski D, Boron-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. Adv Med Sci, 2017,62(2):345-356.
[12] Fiore M, Maraolo AE, Gentile I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging gram-positive spontaneous bacterial peritonitis. World J Hepatol, 2017,9(30):1166-1175.
[13] Alexopoulou A, Papadopoulos N, Eliopoulos DG, et al. Increasing frequency of gram-positive cocci and gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis. Liver Int, 2013,33(7):975-981.
[14] Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology, 2012,55(5):1551-1561.
[15] Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology, 2019,156(5):1368-1380, e10.
[16] Fernandez J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol, 2019,70(3):398-411.
[17] Bolognesi M, Merkel C, Bianco S, et al. Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology, 1994,19(3):628-634.
[18] Nouri-Aria KT, Alexander GJ, Portmann BC, et al. T and B cell function in alcoholic liver disease. J Hepatol, 1986,2(2):195-207.
[19] Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol, 2011,55(5):1010-1016.
[20] Bruns T, Peter J, Reuken PA, et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int, 2012,32(2):223-230.
[21] Casper M, Mengel M, Fuhrmann C, et al. The INCA trial (impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): study protocol for a randomized controlled trial. Trials, 2015,16:83.
[22] Wang C, Chen ZL, Pan ZF, et al. NOD2 polymorphisms and pulmonary tuberculosis susceptibility: a systematic review and meta-analysis. Int J Biol Sci, 2013,10(1):103-108.
[23] 刘娟, 胡国信. 肝硬化并自发性细菌性腹膜炎的预后危险因素分析. 中国医药科学, 2019, 9(21):4.
[24] 张燕, 王全楚, 李娜. 血清PCT检测在肝硬化并发自发性细菌性腹膜炎分级诊疗中的应用价值. 胃肠病学和肝病学杂志, 2016, 25(6):3.
[25] Jones SR. The absolute granulocyte count in ascites fluid. An aid to the diagnosis of spontaneous bacterial peritonitis. West J Med, 1977,126(5):344-346.
[26] Angeloni S, Leboffe C, Parente A, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol, 2008,14(17):2757-2762.
[27] Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther, 2015,41(11):1116-1131.
[28] Agiasotelli D, Alexopoulou A, Vasilieva L, et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int, 2017,37(4):576-582.
[29] Dibas M, Rajab AM, Zaghloul MS, et al. Ascitic calprotectin for the diagnosis of spontaneous bacterial peritonitis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2020,32(9):1075-1083.
[30] Ichou L, Carbonell N, Rautou PE, et al. Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis. Gut, 2016,65(3):536-538.
[31] Yuan LY, Ke ZQ, Wang M, et al. Procalcitonin and C-reactive protein in the diagnosis and prediction of spontaneous bacterial peritonitis associated with chronic severe hepatitis B. Ann Lab Med, 2013,33(6):449-454.
[32] Guler K, Vatansever S, Kayacan SM, et al. High sensitivity C-reactive protein in spontaneous bacterial peritonitis with nonneutrocytic ascites. Hepatogastroenterology, 2009,56(90):452-455.
[33] Kadam N, Acharya S, Shukla S, et al. Ascitic fluid high sensitive C-reactive protein (hs-CRP). A prognostic marker in cirrhosis with spontaneous bacterial peritonitis. J Clin Diagn Res,2016,10(4):OC20-4.
[34] Fernandes SR, Santos P, Fatela N, et al. Ascitic calprotectin is a novel and accurate marker for spontaneous bacterial peritonitis. J Clin Lab Anal, 2016,30(6):1139-1145.
[35] Lesinska M, Hartleb M, Gutkowski K, et al. Procalcitonin and macrophage inflammatory protein-1 beta (MIP-1beta) in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Adv Med Sci, 2014,59(1):52-56.

Spontaneous bacterial peritonitis in patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Nan Yuemin, Li Jiazheng. Liver cirrhosis and infections: the state of the disease [J]. Journal of Practical Hepatology, 2022, 25(5): 609-611.
[2]	Mi Meng,Lu Bingjiu,Wang Xueliang, et al.. Analysis of blood lipid in patients with metabolism-related fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 653-656.
[3]	Luo Suyan, Li Tingting, Wang Yaqi,et al.. Diagnostic performance of peripheral blood Treg/Th17 cells and their related cytokines in predicting significant liver fibrosis in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2022, 25(5): 673-676.
[4]	Gong Hao, Huang Li, Zhang Qinghong, et al.. Diagnostic efficacy of urine microalbumin, β2-microglobulin and N-acetyl-beta-glucosaminidase levels for renal injury in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 681-684.
[5]	Li Ting,Mao Xiaorong, Zhang Xuemei, et al.. Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS [J]. Journal of Practical Hepatology, 2022, 25(5): 685-688.
[6]	Huang Juan, Zhang Jichen. MRI LAVA scanning for collateral circulation in patients with Budd-Chiari syndrome [J]. Journal of Practical Hepatology, 2022, 25(5): 689-692.
[7]	Shi Ying, Bai Genji,Sun Yang. Diagnostic performance of multimodal MRI in differentiating dysplastic nodules and small hepatocellular carcinoma in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 722-725.
[8]	Yang Jing, Cheng Yanli. Idiopathic non-cirrhotic portal hypertension: one case report and literature review [J]. Journal of Practical Hepatology, 2022, 25(5): 750-752.
[9]	Zhang Gaixia, Chen Haizhen, Huang Jing. Intestinal microecology in patients with alcoholic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 757-760.
[10]	Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association. Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 761-S1.
[11]	CheDepartment of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, Chinan Mengqi, Fan Jiangao. Brief introduction of a clinical practice guideline for the diagnosis and management of patients with nonalcoholic fatty liver diseases in USA [J]. Journal of Practical Hepatology, 2022, 25(5): 762-S16.
[12]	Mo Jinying, Yu Xi, Yu Xueping, et al. Diagnostic performance of FibroTouch scan in identifying liver fibrosis in hepatitis B virus carriers [J]. Journal of Practical Hepatology, 2022, 25(4): 480-483.
[13]	Luo Zhenzhen, Tian Haiying, Ge Jianhua, et al. Clinical evaluation of liver fibrosis by serum N-oligosaccharide and bile acid levels and liver stiffness measurement combination in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(4): 504-507.
[14]	Fu Lihong, Gao Yueqiu, Wang XiaoLin, et al. Liver pathological features of patients with drug-induced liver injury: An analysis of 38 cases [J]. Journal of Practical Hepatology, 2022, 25(4): 512-516.
[15]	Ji Xuechun, Jin Shizhu, Nipal Narayan, et al. Endoscopic management of superior esophageal variceal bleeding: a 10-year single center retrospective experience [J]. Journal of Practical Hepatology, 2022, 25(4): 530-533.